About TOT BIOPHARM-B Company

Dongyao Pharmaceutical is a biopharmaceutical company that develops drugs into the clinical stage. It focuses on the development and commercialization of innovative oncology drugs and treatments. The company aims to become a leading oncology treatment brand that medical professionals, patients and their families can trust. Currently, the company has drug combinations under development for various cancers, including monoclonal antibody drugs, antibody-conjugated drugs (ADC), oncolytic virus drugs, and special antineoplastic drugs (such as liposomal drugs). Since its establishment in 2009, the company has established a comprehensive platform integrating drug discovery, product development, quality management, pre-clinical and clinical development, commercial production and marketing, providing flexibility and scalability for the company to carry out business in the innovative pharmaceutical industry value chain. The company has established three comprehensive technology platforms, including a technical platform for therapeutic monoclonal antibodies and antibody-conjugated drugs (ADCs), a therapeutic technology platform based on genetic engineering, and an innovative drug delivery technology platform. Therapeutic monoclonal antibodies and ADC drug technology platforms integrate the company's R&D and production capabilities, enabling the company to develop a series of antibody drugs and ADCs; treatment technology platforms based on genetic engineering integrate anti-tumor immunotherapy, gene therapy and viral therapy to develop and produce recombinant viral vector systems for tumor targets; the innovative drug delivery technology platform covers advanced targeted liposome administration systems, which have key encapsulation technologies for hydrophobic and hydrophilic compounds, which can prevent the encapsulated composition from being broken down and released at the intended target site. Using the above technical platform, Dongyao Pharmaceutical has developed a series of products, established a strong product pipeline, and continued to advance the pre-clinical and clinical development of related drugs under development. With the company's comprehensive industrial value chain capabilities, Dongyao Pharmaceutical has established an open platform business model to cooperate with third parties at different stages of the industrial value chain, complement each other with different industry participants, and reach various forms of cooperation. Dongyao Pharmaceutical has formed a senior management team with rich experience and deep expertise in the field of cancer treatment. The team members' expertise includes preclinical research, clinical development, production, quality control and assurance, and commercialization. The technology covers monoclonal antibodies, ADC drugs, oncolytic virus drugs and special small molecule antineoplastic drugs.